文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气消化、代谢与肾脏急症

危重型COVID-19患者疾病特征与临床管理在疫情过程中的动态变化:前瞻性国际多中心RISC-19-ICU注册研究分析

Dynamics of disease characteristics and clinical management of critically ill COVID-19 patients over the time course of the pandemic: an analysis of the prospective, international, multicentre RISC-19-ICU registry.
PubMed 文献 · Crit Care · 2022-07-04
一句话结论RISC-19-ICU注册研究显示,2020年3月至2021年9月间危重型COVID-19患者趋于年轻、病情减轻,ICU死亡率由23%降至17%,住院时间由14天缩短至11天。

该前瞻性观察性注册研究纳入全球22个国家90个ICU的4041例实验室确诊、需要高级器官支持的危重型COVID-19患者,采用分层广义线性混合效应模型分析疫情持续期间各变量的连续演变。结果显示,随时间推移,ICU入院时患者年龄(62岁 vs 64岁,p<0.001)和器官功能障碍严重程度(SOFA 8.2 vs 5.8,p<0.001)变化,女性患者比例增加(26% vs 41%,p<0.001),症状出现至住院及ICU入住的时间延长(6.7天 vs 9.7天,p<0.001),入院时PaO2/FiO2更低(132 mmHg vs 101 mmHg,p<0.001)但初始5天内改善更快(34 mmHg vs 70 mmHg,p=0.05)。治疗方面,类固醇和托珠单抗使用增加,治疗性抗凝呈倒U形变化,高流量氧疗(5% vs 20%,p<0.001)和无创机械通气(14% vs 24%,p<0.001)使用增加,而有创机械通气减少(82% vs 74%,p<0.001)。ICU死亡率(23% vs 17%,p<0.001)和住院时间(14天 vs 11天,p<0.001)在19个月内下降。

要点

  • 2020年3月至2021年9月,危重型COVID-19患者ICU入院时年龄(62岁 vs 64岁,p<0.001)和SOFA评分(8.2 vs 5.8,p<0.001)变化,女性比例增加(26% vs 41%,p<0.001)。
  • 疫情后期症状出现至住院及ICU入住时间延长(6.7天 vs 9.7天,p<0.001),入院时PaO2/FiO2更低(132 mmHg vs 101 mmHg,p<0.001),但初始5天内改善更快(34 mmHg vs 70 mmHg,p=0.05)。
  • 高流量氧疗(5% vs 20%,p<0.001)和无创机械通气(14% vs 24%,p<0.001)使用增加,有创机械通气减少(82% vs 74%,p<0.001)。
  • 类固醇和托珠单抗使用增加,治疗性抗凝呈倒U形变化。
  • ICU死亡率(23% vs 17%,p<0.001)和住院时间(14天 vs 11天,p<0.001)在19个月内下降。

适用人群与场景

  • 全球22个国家90个ICU的实验室确诊、需要高级器官支持的危重型COVID-19患者,共4041例,纳入时间为2020年3月至2021年9月。

处置流程与药物剂量

  • 疫情过程中,类固醇和托珠单抗使用增加,治疗性抗凝使用呈倒U形变化;高流量氧疗使用从5%增至20%(p<0.001),无创机械通气从14%增至24%(p<0.001),有创机械通气从82%降至74%(p<0.001)。

研究设计与关键结果

  • 研究类型为前瞻性、观察性、国际多中心注册研究,纳入22个国家90个ICU的4041例危重型COVID-19患者,采用分层广义线性混合效应模型分析。
  • 随时间推移,ICU入院时年龄为62岁(95%CI 60-63)vs 64岁(95%CI 62-66),p<0.001;SOFA评分为8.2(95%CI 7.6-9.0)vs 5.8(95%CI 5.3-6.4),p<0.001;女性患者比例为26%(95%CI 23-29)% vs 41%(95%CI 35-48)%,p<0.001。
  • 症状出现至住院及ICU入住时间:6.7天(95%CI 6.2-7.2)vs 9.7天(95%CI 8.9-10.5),p<0.001。
  • 入院时PaO2/FiO2:132 mmHg(95%CI 123-141)vs 101 mmHg(95%CI 91-113),p<0.001;初始5天内PaO2/FiO2改善:34 mmHg(95%CI 20-48)vs 70 mmHg(95%CI 41-100),p=0.05。
  • 高流量氧疗使用:5%(95%CI 4-7)% vs 20%(95%CI 14-29)%,p<0.001;无创机械通气:14%(95%CI 11-18)% vs 24%(95%CI 17-33)%,p<0.001;有创机械通气:82%(95%CI 76-86)% vs 74%(95%CI 64-82)%,p<0.001。
  • ICU死亡率:23%(95%CI 19-26)% vs 17%(95%CI 12-25)%,p<0.001;住院时间:14天(95%CI 13-16)vs 11天(95%CI 10-13),p<0.001。

证据类型、等级与局限

  • 证据类型:前瞻性、观察性、国际多中心注册研究(RISC-19-ICU注册研究)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 疫情过程中危重型COVID-19患者的特征和疾病过程持续演变,临床管理也相应变化,导致ICU人群更年轻、病情更轻,临床、肺部和炎症表现与疫情初期明显不同。

指南或共识出处

  • RISC-19-ICU注册研究,发表于Crit Care。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: It remains elusive how the characteristics, the course of disease, the clinical management and the outcomes of critically ill COVID-19 patients admitted to intensive care units (ICU) worldwide have changed over the course of the pandemic.

METHODS: Prospective, observational registry constituted by 90 ICUs across 22 countries worldwide including patients with a laboratory-confirmed, critical presentation of COVID-19 requiring advanced organ support. Hierarchical, generalized linear mixed-effect models accounting for hospital and country variability were employed to analyse the continuous evolution of the studied variables over the pandemic.

RESULTS: Four thousand forty-one patients were included from March 2020 to September 2021. Over this period, the age of the admitted patients (62 [95% CI 60-63] years vs 64 [62-66] years, p < 0.001) and the severity of organ dysfunction at ICU admission decreased (Sequential Organ Failure Assessment 8.2 [7.6-9.0] vs 5.8 [5.3-6.4], p < 0.001) and increased, while more female patients (26 [23-29]% vs 41 [35-48]%, p < 0.001) were admitted. The time span between symptom onset and hospitalization as well as ICU admission became longer later in the pandemic (6.7 [6.2-7.2| days vs 9.7 [8.9-10.5] days, p < 0.001). The PaO2/FiO2 at admission was lower (132 [123-141] mmHg vs 101 [91-113] mmHg, p < 0.001) but showed faster improvements over the initial 5 days of ICU stay in late 2021 compared to early 2020 (34 [20-48] mmHg vs 70 [41-100] mmHg, p = 0.05). The number of patients treated with steroids and tocilizumab increased, while the use of therapeutic anticoagulation presented an inverse U-shaped behaviour over the course of the pandemic. The proportion of patients treated with high-flow oxygen (5 [4-7]% vs 20 [14-29], p < 0.001) and non-invasive mechanical ventilation (14 [11-18]% vs 24 [17-33]%, p < 0.001) throughout the pandemic increased concomitant to a decrease in invasive mechanical ventilation (82 [76-86]% vs 74 [64-82]%, p < 0.001). The ICU mortality (23 [19-26]% vs 17 [12-25]%, p < 0.001) and length of stay (14 [13-16] days vs 11 [10-13] days, p < 0.001) decreased over 19 months of the pandemic.

CONCLUSION: Characteristics and disease course of critically ill COVID-19 patients have continuously evolved, concomitant to the clinical management, throughout the pandemic leading to a younger, less severely ill ICU population with distinctly different clinical, pulmonary and inflammatory presentations than at the onset of the pandemic.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Wendel-Garcia PD, Moser A, Jeitziner MM, et al. Dynamics of disease characteristics and clinical management of critically ill COVID-19 patients over the time course of the pandemic: an analysis of the prospective, international, multicentre RISC-19-ICU registry. Crit Care. 2022. PMID: 35787726. doi:10.1186/s13054-022-04065-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。